Thrombomodulin (CD141) Human ELISA

Regulatery Status: RUO
Type: Sandwich ELISA, HRP-labelled antibody
Other Names Status: CD141, Cluster of Differentiation 141, BDCA-3
Species: Human
Catalog No Size
Product Catalog No: RGP003R Pack Size: 96 wells (1 kit)

Pack Size:
Pack Size:
Pack Size:
Pack Size:

Category:
Product Features

Thrombomodulin (CD141) is a 557 amino acid a glycosylated transmembrane protein and is a thrombin receptor located on endothelial cell surface. This surface glycoprotein forms a complex with thrombin that activates protein C, which, in turn, degrades clotting factors V and VIII. Thus, thrombomodulin converts thrombin into a physiologic anticoagulant. Thrombomodulin is also found in the circulatory and urinary systems.

Research topic

Cell surface proteins (sCD)

Technical Sheet / Info

Type

Sandwich ELISA, HRP-labelled antibody

Applications

Serum, Plasma, Cell culture supernatant

Sample Requirements

100 µl/well

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.625–20 ng/ml

Limit of Detection

< 0.38 ng/ml

Order Enquiry

Order Enquiry Form

References

– de Leeuw K, Blaauw J, Smit A, Kallenberg C, Bijl M. Vascular responsiveness in the microcirculation of patients with systemic lupus erythematosus is not impaired. Lupus. 2008 Nov;17 (11):1010-7

– de Leeuw K, Freire B, Smit AJ, Bootsma H, Kallenberg CG, Bijl M. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus. 2006;15 (10):675-82

– de Leeuw K, Sanders JS, Stegeman C, Smit A, Kallenberg CG, Bijl M. Accelerated atherosclerosis in patients with Wegener’s granulomatosis. Ann Rheum Dis. 2005 May;64 (5):753-9

– Jie KE, van der Putten K, Bergevoet MW, Doevendans PA, Gaillard CA, Braam B, Verhaar MC. Short- and long-term effects of erythropoietin treatment on endothelial progenitor cell levels in patients with cardiorenal syndrome. Heart. 2011 Jan;97 (1):60-53

– Skrabal CA, Choi YH, Kaminski A, Steiner M, Kundt G, Steinhoff G, Liebold A. Circulating endothelial cells demonstrate an attenuation of endothelial damage by minimizing the extracorporeal circulation. J Thorac Cardiovasc Surg. 2006 Aug;132 (2):291-6

– Yano Y, Kitagawa N, Gabazza EC, Morioka K, Urakawa H, Tanaka T, Katsuki A, Araki-Sasaki R, Hori Y, Nakatani K, Taguchi O, Sumida Y, Adachi Y. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J Clin Endocrinol Metab. 2003 Feb;88 (2):736-41

Enquiry